Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is a progressive disorder characterized by emphysema and chronic bronchitis resulting in the destruction of pulmonary parenchyma and narrowing of the airways ([@B44]; [@B60]; [@B62]). Cigarette smoke (CS) is the principal risk of causing COPD ([@B54]), exposing the lungs to an excessive quantity of free radicals, carcinogens and reactive oxygen species (ROS), which trigger endoplasmic reticulum (ER) stress ([@B27]).The ER attempts to restore cellular homeostasis through the unfolded protein response (UPR) which is an evolutionarily conserved biochemical pathway ([@B55]). The UPR reduces accumulation of abnormally folded proteins in the ER through increased protein degradation and production of chaperone proteins and a decrease in protein translation, thereby promoting cell survival ([@B51]). If these initiatives fail to restore cellular homeostasis, programmed cell death (apoptosis) may be initiated by the UPR ([@B32]; [@B50]; [@B55]). Through the detection of proteins characteristic of the UPR, including glucose-regulated protein 78 (GRP78), calreticulin and calnexin, ER stress has been shown to occur in patients with COPD ([@B40]; [@B46]). In addition, these UPR proteins have been shown to be up-regulated in chronic smokers in comparison with nonsmokers ([@B27]), indicating a plausible role for ER stress and UPR activation in smoking, possibly resulting in cell death, and disease ([@B19]; [@B21]).

Jianpiyifei II granules (JPYF II) are composed of a mixture of eight traditional Chinese medicines (TCMs) \[*Astragalus membranaceus* (Fisch.) Bunge, *Cimicifuga foetida* L., *Codonopsis pilosula* (Franch.) Nannf., *Atractylodes macrocephala* koidz., *Bupleurum chinense* DC., *Cynomorium songaricum* Rupr., *Vitex negundo* L. and *Prunus persica* (L.) Batsch\] and are prescribed for the treatment of COPD in Guangdong Provincial Hospital of Chinese Medicine. The major components of JPYF II have been analyzed using UPLC/ESI/HRMS in a previous study ([@B12]). In addition, previous clinical studies have demonstrated that JPYF II is able to substantially decrease the St. George's Respiratory Questionnaire (SGRQ) score and increase the 6-minute walk distance (6MWD) in 178 COPD patients whose condition was judged stable ([@B61]). Additionally, our previous *in vivo* and *in vitro* studies have demonstrated that JPYF II exhibits anti-oxidative and anti-inflammatory properties in mice and rats exposed to cigarette smoke (CS) and lipopolysaccharide (LPS), and in RAW264.7 cells stimulated with cigarette smoke extract (CSE), indicating that it has a protective effect against COPD ([@B33]; [@B34]; [@B12]). Whether JPYF II can reduce CS-induced apoptosis of bronchial epithelial cells in COPD or whether the protective effect of JPYF II is related to ER stress remains unclear.

In the present study, JPYF II was demonstrated to suppress apoptosis and overexpression of ER stress-related proteins in bronchial epithelial cells from the lung tissues of CS-exposed mice. Furthermore, mechanistic investigation indicated that its anti-apoptotic effects were associated with interruption of the ROS-ER stress-Ca^2+^ signaling pathway. Hence, our results provide a theoretical basis for the clinical application of JPYF II in the treatment of COPD.

Materials and Methods {#s2}
=====================

JPYF II Preparation {#s2_1}
-------------------

JPYF II consists of *A. membranaceus*, *C. foetida*, *C. pilosula*, *A. macrocephala*, *B. chinense*, *C. songaricum*, *V. negundo*, and *P. persica* in a ratio of 3:1:3:1.5:1:1.5:1.5:1 as shown in [**Table S1**](#SM1){ref-type="supplementary-material"}. All the herbs purchased from Guangdong Provincial Hospital of Chinese Medicine were deposited in the Second Clinical College of Guangzhou University of Chinese Medicine (voucher specimen nos. 160717, 160718, 160719, 160720, 160721, 160722, 160723, and 160724). The medicinal herbal powders were extracted twice with boiling water (10 times the volume of the herbs) for 1.5 h. Each water extract was filtered and dehydrated under vacuum conditions and then residue was freeze-dried and stored in a refrigerator until required ([@B12]).

LC/MS Analysis {#s2_2}
--------------

Chromatographic analysis was performed using a Thermo Fisher Accela UPLC system (Thermo Fisher Scientific, San Jose, CA, United States) equipped with a quaternary pump solvent management system, an online degasser, a diode-array detector (DAD), a column compartment, and an auto-sampler using a Phenomenex UPLC Kinetex C18 column (2.1 × 100 mm, 1.7 μm). Chromatographic separation conditions were as follows: Flow rate: 0.2 ml/min; Injection volume: 3 μl; Column temperature: 25°C; Mobile phase A: an aqueous solution of 0.1% formic acid; Mobile phase B: acetonitrile; An elution gradient: 5%--25% B from 0--5 min, 25%--60% B from 5--28 min, 60%--90% B from 28--38 min and 90% B between 38--42 min; Detection wavelengths: 214, 254, and 280 nm. Mass spectrometry (MS) was performed using a Thermo Fisher Accela LTQ Orbitrap XL hybrid mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with an electrospray ionization (ESI) interface. The ESI source was set in positive ionization mode. MS acquisition was set with a scan range of 150--1300 m/z and a resolving power of 30,000 for full-scan ([@B12]).

Preparation of High Performance Liquid Chromatography (HPLC) Sample and HPLC Analysis {#s2_3}
-------------------------------------------------------------------------------------

To prepare HPLC sample solution of JPYF II, *A. membranaceus* (50 g), *C. foetida* (16 g), *C. pilosula* (50 g), *A. macrocephala* (25 g), *B. chinense* (16 *g*), *C. songaricum* (25 g), *V. negundo* (25 g), and *P. persica* (16 g) were mixed, soaked in 10 times (v/w) pure water, then boiled for 1.5 h and filtered. The extraction procedure was performed twice. The two filtrates were merged and evaporated with rotary evaporation under vacuum at 60°C. The final volume of concentrated solution was 200 ml. For HPLC analysis, 10 ml of above concentrated solution was centrifuged at 4,000 rpm for 5 min and the supernatant was evaporated. Subsequently, the residue was dissolved with 2 ml of methanol and filtered through a 0.45 μm filter before HPLC analysis. At the same time, the standards of calycosin and calycosin-7-*O*-*β*-D-glucoside were accurately weighed, mixed, and dissolved in methanol to prepare a mixed standard solution, which was diluted before HPLC analysis to establish a standard curve.

Agilent 1200 HPLC (Agilent Technologies, Santa, Clara, CA, United States) equipped with Inertsil C18 column (4.6 × 250 mm, 5 μm) was used for HPLC analysis. Chromatographic separations were performed at 30°C with flow rate of 1.0 ml/min. The injection volume was 15 μl, and the ultraviolet detection wavelength was set as 260 nm. The mobile phase consisted of water (A) with 0.1% phosphoric acid (v/v) and acetonitrile (B). The gradient elution conditions of the mobile phase B were: 0--6 min, 10%--20%; 6--17 min, 20%--20.4%; 17--35 min, 20.4%--40%; 35--40 min, 40%--60%; 40--45 min, 60%--85%; 45--50 min, 85%--90%.

Ethics Statement {#s2_4}
----------------

Balb/c female mice (specific pathogen-free and 6 to 8 weeks old) were purchased from the Animal Supply Center of Guangdong Academy of Medical Science, Foshan, China. All animals were housed under standard conditions in the Animal Center of Guangdong Provincial Academy of Chinese Medical Sciences at 25 ± 1°C temperature and 55 ± 5% humidity under a 12 h light/dark cycle with free access to water and food. All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangdong Provincial Academy of Chinese Medical Sciences (Approval number: 2018006).

Animal Treatment {#s2_5}
----------------

Specifically pathogen-free 6 to 8 week-old female Balb/c mice were placed in an 18 L Perspex chamber (18 cm × 25 cm × 40 cm) and received CS generated from four cigarettes/day for 30 days. CS from one cigarette was delivered for 30 min at each of the following times: 11:00, 12:30, 14:00, and 15:30 every day. To mimic the rate of cigarette combustion and the normal quantity of smoke inhalation, CS was collected in a syringe (50 ml) over 10 s. Control mice were instead exposed to fresh air using the same experimental setup. Filter-tipped HongShuangXi cigarettes (manufactured by Guangdong China Tobacco Industry Co., Ltd) emitting 11 mg tar, 1.2 mg nicotine, and 13 mg CO per cigarette were used in this study. From the third week of CS exposure, JPYF II was administered intragastrically to mice at low (0.75 g/kg/d), medium (1.5 g/kg/d) and high (3 g/kg/d) concentrations respectively. The same volume of saline was injected intragastrically in control mice and model mice.

Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling (TUNEL) Staining Assay {#s2_6}
--------------------------------------------------------------------------------------------

Apoptosis of the bronchial epithelial cells in the lung tissues of the mice was evaluated by TUNEL staining. Briefly, paraffin-embedded lung tissue sections were cut into a thickness of 3 μm and dried overnight at 37°C. Following deparaffinization in xylene twice for 10 min each, the sections were then rehydrated through an increasing gradient of alcohol concentrations. The sections were then treated with 20 mg/ml proteinase K to strip proteins from the nuclei. The sections were incubated with 3% H~2~O~2~ for 30 min at room temperature to block endogenous peroxidase and then sequentially with TdT enzyme, biotin, dUTP, Streptavidin-HRP, and DAB, prior to staining with hematoxylin. Three visual fields were randomly selected from each tissue section, and three pieces of each group were taken. TUNEL positive cells in each slice were then imaged using an automated imaging microscope (OLYMPUS BX61, Tokyo, Japan), and calculated by randomly choosing three different fields of bronchial region at × 400 magnification. ImageJ software was used to count the number of cells in images. The degree of apoptosis was evaluated by an index calculated from the ratio of TUNEL-positive bronchial epithelial cells to the total number of bronchial epithelial cells.

Immunohistochemistry {#s2_7}
--------------------

Mouse lung tissues were fixed in 10% formalin in phosphate-buffered saline (PBS) for 24 h, prior to paraffin embedding and immunohistochemical staining. Briefly, deparaffinized and fixed sections were then incubated overnight at 4°C with primary antibodies against GRP78 (1:200, Abcam, Cambridge, United Kingdom), p-eIF2α (1:200, Cell Signaling Technology, Danvers, MA, United States) and CHOP (1:200, Cell Signaling Technology, Danvers, MA, United States) respectively after which they were incubated with the corresponding secondary antibodies at room temperature for 30 min. 3,3′-Diaminobenzidine tetrahydrochloride was used as a chromogenic agent according to the manufacturer's instructions. Finally, the sections were counterstained with Mayer's hematoxylin, then observed using upright light microscopy (Leica Microsystem, CA, United States).

Cell Culture and Cell Viability {#s2_8}
-------------------------------

Human bronchial epithelial cell lines (BEAS-2B and 16-HBE) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in glucose-Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY, United States) containing 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin and maintained at 37°C in an atmosphere of saturated humidity containing 5% CO~2~. CSE preparation has been described previously ([@B12]). BEAS-2B and 16-HBE cells were seeded in 96-well plates at a density of 5 × 10^3^ cells/well and then treated with CSE and JPYF II respectively. Additionally, both of two cell lines were exposed to CSE, followed by treatment with JPYF II. Cell viability was examined using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, in accordance with the manufacturer's instructions. Optical absorbance was measured using a VersaMax Microplate Reader (PerkinElmer, Waltham, MA, United States).

Analysis of Cell Apoptosis: Flow Cytometry Assay and Hoechst Staining {#s2_9}
---------------------------------------------------------------------

BEAS-2B and 16-HBE cells were cultured in 6-well cell culture plates, exposed to CSE, then treated with JPYF II, and washed twice with PBS prior to additional processing. Cells were resuspended in 500 μl of binding buffer then stained with 5 μl of Annexin V-fluorescein isothiocyanate (FITC) and 5 μl of propidium iodide (PI) (BD Biosciences, San Diego, CA, United States) for 15 min at room temperature in the dark. Finally, the cells were analyzed by flow cytometry (BD Biosciences, Franklin Lakes, NJ, United States) using BD FACS Diva software.

BEAS-2B and 16-HBE cells were seeded into 6-well cell culture plates, exposed to CSE, then treated with JPYF II, and washed twice with PBS. Cells were stained with Hoechst 33342 (Beyotime, Shanghai, China) for 25 min at 4°C in the dark. Changes in morphology were observed using fluorescence microscopy (Leica DMI3000B, Wetzlar, Germany) using a filter for Hoechst 33342 (365 nm).

Cell Cycle Analysis {#s2_10}
-------------------

After exposure to CSE and then treatment with JPYF II for 48 h, the BEAS-2B and 16-HBE cells were centrifuged, fixed and permeabilized overnight at -20°C in 70% ethanol. The cells were then washed with PBS and incubated for 30 min at room temperature with 5 mg/ml PI and 1 mg/ml RNase (Lianke, Nanjing, China). Finally, all samples were analyzed by flow cytometry (BD Biosciences, Franklin Lakes, NJ, United States).

Western Blot Analysis {#s2_11}
---------------------

BEAS-2B and 16-HBE cells were harvested and lysed in ice-cold lysis buffer for 30 min. Protein concentration was measured using bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, Waltham, MA, United States). Normalized quantities of protein (25 μg) were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were then transferred to polyvinylidene fluoride (PVDF) membranes which were then blocked with 5% bovine serum albumin (BSA) and incubated overnight at 4°C with primary antibodies against Caspase-3 (1:1000, Cell Signaling Technology, Danvers, MA, United States), Bax (1:1000, Cell Signaling Technology, Danvers, MA, United States), Bcl-2 (1:1000, Cell Signaling Technology, Danvers, MA, United States), GRP78 (1:1000, Abcam, Cambridge, United Kingdom), PERK (1:1000, Cell Signaling Technology, Danvers, MA, United States), p-PERK (1:1000, Affinity Biosciences, ChangZhou, Jiangsu, China), elF2α (1:1000, Cell Signaling Technology, Danvers, MA, United States), p-eIF2α (1:1000, Cell Signaling Technology, Danvers, MA, United States), and CHOP (1:1000, Cell Signaling Technology, Danvers, MA, United States), respectively. After being washed with Tris-buffered saline-Tween 20 (TBST), the membranes were incubated withspecies-specific HRP-conjugated secondary antibodies for 2 h, and the immunoreactive bands were visualized using a chemiluminescence detection system (Pierce, Rockford, IL, United States). Quantity One software (Bio-Rad, Hercules, CA, United States) was used to quantify band intensity. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:1000, Cell Signaling Technology, Danvers, MA, United States) or β-actin (1:1000, Cell Signaling Technology, Danvers, MA, United States) was used as an endogenous control.

Measurement of Intracellular ROS or Ca^2+^ {#s2_12}
------------------------------------------

BEAS-2B and 16-HBE cells, which were exposed to CSE and treated with indicated samples, were then stained with 10 μM 2′,7′-dichlorofluorescein diacetate (DCF-DA) (Beyotime, Shanghai, China) for 30 min at 37°C in the dark. ROS generation was then measured by flow cytometry (BD Biosciences, Franklin Lakes, NJ, United States) at 525 nm. Intracellular calcium concentration in the BEAS-2B and 16-HBE cells was observed by flow cytometry following incubation of the cells with 5 μM of the molecular probe Fluo-4/AM (Beyotime, Shanghai, China) for 30 min at 37°C.

Statistical Analysis {#s2_13}
--------------------

Data from all experiments are expressed as means ± standard deviation (SD). Statistical significance was determined using a one-way analysis of variance (ANOVA) with a Tukey's multiple comparison test. *P*-values \< 0.05 were considered statistically significant.

Results {#s3}
=======

Identification and Concentration Detection of Major Components in JPYF II Using UPLC-ESI-HRMS and HPLC {#s3_1}
------------------------------------------------------------------------------------------------------

By comparing retention time, mass difference and protonated molecular ion mass number of peaks in the total ion chromatogram (TIC) of JPYF II with those of standards and literature data ([**Figure S1**](#SM1){ref-type="supplementary-material"}), a preliminary identification of components in JPYF II was performed, as listed in [**Table S2**](#SM1){ref-type="supplementary-material"}. In addition, the control characteristic map (chromatogram) of JPYF II was shown in [**Figure S2**](#SM1){ref-type="supplementary-material"}. The contents of calycosin and calycosin-7-*O*-*β*-D-glucoside in JPYF II were 3.95 μg/ml and 8.11 μg/ml, respectively.

JPYF II Inhibits Apoptosis and ER Stress in Bronchial Epithelial Cells in Mouse Lung Tissue Stimulated by CS {#s3_2}
------------------------------------------------------------------------------------------------------------

Compared with the control group (3.94% ± 3.25%), the number of TUNEL-positive cells was greater in the bronchial epithelium of mice exposed to CS (73.54% ± 4.34%), while the proportion of TUNEL-positive cells in the JPYF II treatment groups (low: 19.87% ± 16.28%; middle: 4.32% ± 0.59%; high: 4.90% ± 1.79%) was lower than that of the model group ([**Figures 1A, B**](#f1){ref-type="fig"}).

![JPYF II alleviated CS-induced apoptosis and ER stress in bronchial epithelial cells in mouse lung tissue. **(A)** Representative photomicrographs showing brown TUNEL staining cells in bronchial region of lung sections from control, model and JPYF II-treated mice (low: 0.75 g/kg/d; middle: 1.5 g/kg/d; high: 3 g/kg/d). Scale bars = 100, 50μm. **(B)** Quantification of the TUNEL-staining cells. **(C)** Representative photomicrographs from immunohistochemistry (IHC) for GRP78, p-eIF2α and CHOP. Scale bars = 100 μm. Values are presented as means ± SD. ^\#\#\#^*P* \< 0.001 compared with control mice; ^\*\*\*^*P* \< 0.001 compared with model mice (n = 6 per group).](fphar-11-00581-g001){#f1}

Immunohistochemical staining revealed that expression of GRP78, phosphorylation of eukaryotic initiation factor 2α (p-eIF2α) and CCAAT-enhancer-binding protein homologous protein (CHOP) in bronchial epithelial cells in the control group was quite low (shown as brown staining), but significantly greater in cells from the model group, and considerably less in the JPYF II treatment groups than in the model group ([**Figure 1C**](#f1){ref-type="fig"}).

The Influence of CSE and JPYF II on Bronchial Epithelial Cell Viability {#s3_3}
-----------------------------------------------------------------------

The cytotoxicity of CSE and JPYF II was assessed using an MTT assay. Different intervention time points (3, 6, 12, and 24 h) and concentrations of CSE (2.5%, 5%, 10%, 20%, and 40%) were tested. CSE affected cell viability in a time- and dose-dependent manner. Twelve hours of challenge to BEAS-2B cells with 5% CSE (56.7 ± 2.9%) and 24 h of exposure of 16-HBE cells to 10% CSE (55.2 ± 0.7%) were the conditions selected for the follow-up experiments ([**Figures 2A, B**](#f2){ref-type="fig"}). In addition, the cytotoxicity of JPYF II on BEAS-2B and 16-HBE cells was also evaluated. The cells were treated with various concentrations of JPYF II (12.5, 25, 50, 100, 200, 400, and 800 μg/ml) for 48 h, and no significant cytotoxicity was observed except for treatment with 800 μg/ml JPYF II ([**Figure 2C**](#f2){ref-type="fig"}). Furthermore, both of two cell lines were exposed to CSE, followed by treatment with JPYF II. The results indicated that JPYF II was able to attenuate CSE-induced cellular damage and improve cell viability in both BEAS-2B and 16-HBE cells ([**Figure 2D**](#f2){ref-type="fig"}).

![Effects of CSE and JPYF II on bronchial epithelial cell viability. **(A, B)** The MTT assay showed the effects of different concentrations of CSE at different time on BEAS-2B and 16-HBE cell viability. **(C)** The MTT assay showed the effects of JPYF II on BEAS-2B and 16-HBE cell viability. Results are presented by 3 independent experiments (n = 3). Values are presented as means ± SD. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 compared with 0 μg/ml JPYF II group. **(D)** The MTT assay showed the effects of JPYF II on CSE-stimulated BEAS-2B and 16-HBE cell viability. Results are presented by three independent experiments (n = 3). Values are presented as means ± SD. ^\#\#\#^*P* \< 0.001 compared with control group; ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 compared with CSE group.](fphar-11-00581-g002){#f2}

JPYF II Inhibits CSE-Induced Apoptosis in Bronchial Epithelial Cells {#s3_4}
--------------------------------------------------------------------

Exposure to CSE resulted in typical apoptotic changes in BEAS-2B and 16-HBE cells compared with the cells in the control groups, as detected by Annexin V-FITC/PI analysis. Treatment with JPYF II for 48 h significantly reduced the severity of apoptosis compared with the CSE groups ([**Figure 3A**](#f3){ref-type="fig"}). Meanwhile, Hoechst staining demonstrated that in the control groups, even and diffuse blue fluorescence was visible in the nuclei of the BEAS-2B and 16-HBE cells. The characteristic morphological changes typical of apoptosis were observed, in addition to the appearance of high fluorescence intensity in the BEAS-2B cells exposed to 5% CSE for 12 h and 16-HBE cells exposed to 10% CSE for 24 h. Treatment with JPYF II (200 and 400 μg/ml) for 48 h resulted in a significant reduction in morphological changes in the nuclei due to apoptosis in both BEAS-2B and 16-HBE cells, suggesting that JPYF II reduces CSE-induced bronchial epithelial cell apoptosis ([**Figure 3B**](#f3){ref-type="fig"}).

![JPYF II inhibits CSE-induced apoptosis in bronchial epithelial cells. **(A)** Detection of apoptosis in BEAS-2B and 16-HBE cells by flow cytometry. **(B)** Detection of apoptosis in BEAS-2B and 16-HBE cells by Hoechst 33342 staining. Results are presented by three independent experiments (n = 3). Values are presented as means ± SD. ^\#\#\#^*P* \< 0.001 compared with control group; ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 compared with CSE group.](fphar-11-00581-g003){#f3}

JPYF II Inhibits CSE-Induced Cell Cycle Arrest {#s3_5}
----------------------------------------------

Cell cycle analysis was conducted to determine whether JPYF II can inhibit CSE-induced cell cycle arrest in bronchial epithelial cells. The results indicated that, in the control groups, there were 45.57% BEAS-2B and 48.14% 16-HBE cells in G1 phase, and 39.77% and 43.57% in the S phase, respectively. Following exposure to CSE, the proportion of cells in G1 phase increased to 77.89% and 78.58%, respectively, and 17.68% and 17.26% in S phase, respectively. However, treatment with a variety of JPYF II concentrations reversed this effect, the percentages of cells in G1 and S phases recovering ([**Figures 4A, B**](#f4){ref-type="fig"}).

![JPYF II inhibits CSE-induced cell cycle arrest. **(A)** Diagram of cell cycle analysis in BEAS-2B cells by flow cytometry and statistical analysis of G1, S, and G2 populations in BEAS-2B cells. **(B)** Diagram of cell cycle analysis in 16-HBE cells by flow cytometry and statistical analysis of G1, S, and G2 populations in 16-HBE cells.](fphar-11-00581-g004){#f4}

JPYF II Regulates Apoptosis- and ER Stress-Related Protein Expression in CSE-Stimulated Bronchial Epithelial Cells {#s3_6}
------------------------------------------------------------------------------------------------------------------

Western blot analysis demonstrated that CSE stimulation increased the expression levels of cleaved-caspase-3 and the proapoptotic protein bax and reduced the level of the antiapoptotic protein bcl-2 in both BEAS-2B and 16-HBE cells. These changes were abolished by treatment with JPYF II. In addition, Western blot results also revealed that protein expression levels of ER stress-related GRP78, phosphorylation of protein kinase R (PKR)-like endoplasmic reticulum kinase (p-PERK), p-eIF2α and CHOP increased significantly after exposure to CSE compared with the control groups, whereas treatment with JPYF II decreased the protein expression of GRP78, p-PERK, p-eIF2α, and CHOP induced by CSE, suggesting that JPYF II potentially protects against CSE-induced ER stress ([**Figures 5A, B**](#f5){ref-type="fig"}).

![JPYF II regulates apoptosis- and ER stress-related protein expression in CSE-stimulated bronchial epithelial cells. **(A)** Detection of protein expression levels of caspase-3, cleaved-caspase-3, bax and bcl-2 in BEAS-2B and 16-HBE cells by Western blot. **(B)** Detection of protein expression levels of GRP78, PERK, p-PERK, eIF2α, p-eIF2α, and CHOP in BEAS-2B and 16-HBE cells by Western blot. Results are presented by three independent experiments (n = 3). Values are presented as means ± SD. ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 and ^\#\#\#^*P* \< 0.001 compared with control group; ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 compared with CSE group.](fphar-11-00581-g005){#f5}

JPYF II Diminishes CSE-Induced Bronchial Epithelial Cell Death Through the ROS-ER Stress Pathway {#s3_7}
------------------------------------------------------------------------------------------------

The probable involvement of ROS production in CSE-induced cell death and ER stress was evaluated. Flow cytometry revealed that exposure to CSE increased the levels of ROS. However, in addition to reducing the production of ROS induced by CSE ([**Figure 6A**](#f6){ref-type="fig"}), treatment with both JPYF II (200 μg/ml) and the ROS scavenger N-acetyl-L-cysteine (NAC) diminished CSE-induced ER stress and cell death ([**Figures 6B, C**](#f6){ref-type="fig"}), indicating that generation of ROS induced by CSE acts as an upstream effector of ER stress, and that JPYF II reduces the death of bronchial epithelial cells induced by CSE *via* the ROS-ER stress signaling pathway.

![JPYF II diminishes CSE-induced bronchial epithelial cell death through the ROS-ER stress pathway. **(A)** Detection of the inhibitory effects of JPYF II and NAC on CSE-induced ROS generation by flow cytometry. **(B)** Detection of the inhibitory effects of JPYF II and NAC on CSE-induced ER stress by Western blot. **(C)** Detection of the effects of JPYF II and NAC on CSE-stimulated BEAS-2B and 16-HBE cell viability by the MTT assay. Results are presented by three independent experiments (n = 3). Values are presented as means ± SD. ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 and ^\#\#\#^*P* \< 0.001 compared with control group; ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 compared with CSE group.](fphar-11-00581-g006){#f6}

JPYF II Inhibits CSE-Induced Bronchial Epithelial Cell Death Through the ER Stress-Ca^2+^ Pathway {#s3_8}
-------------------------------------------------------------------------------------------------

Because the ER is the principal intracellular reservoir of Ca^2+^, the ER stress inhibitor tauroursodeoxycholic acid (TUDCA) was used to investigate the relationship between intracellular Ca^2+^ levels and CSE-induced ER stress. Flow cytometry using the Ca^2+^ indicator Fluo-4 revealed that exposure to CSE significantly increased intracellular Ca^2+^ concentration, while treatment with both JPYF II (200 μg/ml) and TUDCA, which reduced the expression of ER stress-related proteins ([**Figure 7A**](#f7){ref-type="fig"}), decreased the production of Ca^2+^ ([**Figure 7B**](#f7){ref-type="fig"}). MTT assay results demonstrated that TUDCA substantially inhibited CSE-induced cell death ([**Figure 7C**](#f7){ref-type="fig"}). Interestingly, in addition to reducing CSE-induced Ca^2+^ production ([**Figure 7D**](#f7){ref-type="fig"}), both JPYF II (200 μg/ml) and the Ca^2+^ scavenger BAPTA-AM inhibited CSE-induced ER stress and cell death ([**Figures 7E, F**](#f7){ref-type="fig"}). Furthermore, as the principal Ca^2+^ release channel from the ER to the cytoplasm, the role of IP~3~R in the rise of intracellular Ca^2+^ concentration induced by CSE was tested using the selective inhibitor of IP~3~R, 2-aminoethoxydiphenyl borate (2-APB). Both JPYF II (200 μg/ml) and 2-APB not only decreased intracellular Ca^2+^ levels ([**Figure 7G**](#f7){ref-type="fig"}), they also reduced CSE-induced ER stress and cell death ([**Figures 7H, I**](#f7){ref-type="fig"}). The results presented above indicate that CSE-induced ER stress triggers Ca^2+^ mobilization from the ER to the cytosol and that the release of Ca^2+^ from the ER mediated by IP~3~R is crucial to ER stress. Thus, JPYF II inhibits the death of bronchial epithelial cells induced by CSE *via* the ER stress-Ca^2+^ signaling pathway.

![JPYF II inhibits CSE-induced bronchial epithelial cell death through the ER stress-Ca^2+^ pathway. **(A)** Detection of the inhibitory effects of JPYF II and TUDCA on CSE-induced ER stress by Western blot. **(B)** Detection of the inhibitory effects of JPYF II and TUDCA on CSE-induced Ca^2+^ generation by flow cytometry. **(C)** Detection of the effects of JPYF II and TUDCA on CSE-stimulated BEAS-2B and 16-HBE cell viability by the MTT assay. **(D)** Detection of the inhibitory effects of JPYF II and BAPTA-AM on CSE-induced Ca^2+^ generation by flow cytometry. **(E)** Detection of the inhibitory effects of JPYF II and BAPTA-AM on CSE-induced ER stress by Western blot. **(F)** Detection of the effects of JPYF II and BAPTA-AM on CSE-stimulated BEAS-2B and 16-HBE cell viability by the MTT assay. **(G)** Detection of the inhibitory effects of JPYF II and 2-APB on CSE-induced Ca^2+^ generation by flow cytometry. **(H)** Detection of the inhibitory effects of JPYF II and 2-APB on CSE-induced ER stress by Western blot. **(I)** Detection of the effects of JPYF II and 2-APB on CSE-stimulated BEAS-2B and 16-HBE cell viability by the MTT assay. Results are presented by three independent experiments (n = 3). Values are presented as means ± SD. ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 and ^\#\#\#^*P* \< 0.001 compared with control group; ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 compared with CSE group.](fphar-11-00581-g007){#f7}

Discussion {#s4}
==========

In the present study, our findings indicate that JPYF II significantly inhibited bronchial epithelial cell apoptosis in mice exposed to CS and apoptosis of human bronchial epithelial cell lines (BEAS-2B and 16-HBE) stimulated with CSE. Mechanistically, CSE initially induced intracellular ROS production, triggering ER stress and then Ca^2+^ release from the lumens of the ER, leading finally to apoptosis. Treatment with JPYF II substantially attenuated CSE-induced apoptosis through interruption of the ROS-ER stress-Ca^2+^ signaling pathway.

JPYF II is composed of eight herbs and main components of JPYF II *via* LC/MS analysis include amygdalin, calycosin-7-*O*-*β*-D-glucoside, lobetyolin, vitedoin A, isomer of vitedoin A, calycosin-7-*O*-*β*-D-glycoside-6"-*O*-acetate, ononin, calycosin, formononetin-7-*O*-*β*-D-glycoside-6"-*O*-acetate, formononetin, astragaloside II, saikosaponin A, atractylenolide I, atractylenolide III, astragaloside I/isoastragaloside I, saikosaponin D, and atractylenolide II ([**Figure S1**](#SM1){ref-type="supplementary-material"} and [**Table S2**](#SM1){ref-type="supplementary-material"}). In addition, concentrations of calycosin and calycosin-7-*O*-*β*-D-glucoside in JPYF II were analyzed using HPLC ([**Figure S2**](#SM1){ref-type="supplementary-material"}). The above results give a scientific data for JPYF II to serve as a stable subject of pharmacological experiment in our present study. Interestingly, compounds isolated from these eight medical herbs have been reported to display similar apoptosis inhibitory effect. Astragaloside IV, one of the main and active ingredients of *A. membranaceus*, has been demonstrated to possess anti-oxidative and anti-apoptotic effects ([@B49]; [@B36]; [@B63]; [@B58]), as well as inhibitory effect on ER stress ([@B20]). Furthermore, atractylodesin III from *C. pilosula* ([@B6]), atractylenolide I and atractylenolide III from *A. macrocephala* ([@B41]; [@B65]), saikosaponin C and saikosaponin D from *B. chinense* ([@B30]; [@B56]; [@B35]), and vitegnoside and vitexilactone from *V. negundo* ([@B59]; [@B10]), as well as polysaccharides from *A. membranaceus*, *A. macrocephala* and *C. songaricum*, have been shown to have protective effects against apoptosis ([@B57]; [@B65]; [@B52]). Further study is needed to figure out which chemical components are responsible for suppressing apoptosis of bronchial epithelial cells in COPD *via* inhibition of ROS-ER Stress-Ca^2+^ signaling pathway.

A number of mechanisms are involved in the progression of COPD: oxidative stress, inflammatory cell influx into the lung tissue and protease-antiprotease imbalance ([@B1]; [@B8]; [@B2]). In addition, an increasing number of studies have shown that apoptosis of pulmonary endothelial and epithelial cells may contribute to the pathogenesis of COPD and be possibly an essential upstream effector in its progression ([@B9]; [@B15]). In patients with COPD, there is an increase in the apoptosis of structural cells in the lungs not counterbalanced by increased proliferation of these cells, resulting in a destruction of pulmonary parenchyma and the development of emphysema ([@B18]; [@B15]). Vascular endothelial growth factor (VEGF), various caspases and Bcl-2 family proteins, and others, have been shown to be associated with apoptosis of epithelial and endothelial cells ([@B24]; [@B25]; [@B7]; [@B18]; [@B22]). In the present study, JPYF II inhibited apoptosis in the bronchial epithelial cells of lung tissues in mice exposed to CS and in CSE-stimulated BEAS-2B and 16-HBE cells. In addition, protein expression levels of cleaved-caspase-3 and the proapoptotic protein bax increased and the antiapoptotic protein bcl-2 decreased in CSE-stimulated BEAS-2B and 16-HBE cells, changes that were attenuated by treatment with JPYF II. These results suggest that JPYF II may protect against the apoptosis of bronchial epithelial cells in COPD.

It has been established that apoptosis, the most studied form of programmed cell death ([@B13]), is regulated by a number of different pathways, including the death receptor-mediated extrinsic pathway, cytolytic effector cell pathway, growth factor depletion pathway, mitochondrial intrinsic pathway and the ER pathway ([@B28]; [@B9]; [@B11]; [@B29]; [@B48]). In eukaryotic cells, the ER acts as an essential center for the synthesis and folding of secretory proteins. When cells suffer from stressors such as a change in pH, viral infection, ischemia, toxic challenge, and others, unfolded or misfolded proteins accumulate in the lumens of the ER, resulting in ER stress ([@B31]). The ER attempts to re-establish cellular homeostasis through an increase in unfolded protein degradation, up-regulation of chaperone protein production and suppression of protein synthesis ([@B23]). However, if these adaptive responses of the UPR fail to adequately compensate, apoptotic signals may be initiated ([@B50]).

It has been reported that ER stress is associated with a variety of diseases including neurodegenerative diseases (polyglutamine disease, Alzheimer's disease and Parkinson's disease) ([@B26]; [@B17]; [@B42]), metabolic syndrome ([@B43]), diabetes ([@B16]) and chronic lung diseases (asthma, idiopathic pulmonary fibrosis and COPD) ([@B46]; [@B60]; [@B5]). As the leading cause of COPD, CS not only increases ER stress and activates the UPR, but also increases the degree of apoptosis ([@B53]). Studies in chronic smokers and COPD patients have shown that ER stress and UPR activation have occurred by measuring relevant markers, including GRP78, PERK, eIF2α and CHOP, indicating a possible role of ER stress and prolonged UPR activation that result in cell death and COPD ([@B37]; [@B14]). In addition, both *in vivo* experiments in mice and *in vitro* experiments using airway epithelial cells have strengthened these results by demonstrating that CS and CSE generate a similar response ([@B19]). In the *in vitro* and *in vivo* experiments in the present study, increased production of ER stress-related GRP78, p-PERK, p-eIF2α and CHOP proteins induced by CS and CSE was attenuated by treatment with JPYF II. These results demonstrate that JPYF II may suppress apoptosis in bronchial epithelial cells through the regulation of ER stress.

Previous studies have demonstrated that oxidative stress contributes to the pathogenesis of COPD ([@B45]; [@B38]). ROS, not necessarily generated due to CS *per se*, may be generated as a result of pathologic conditions, and is closely associated with ER stress. High concentrations of ROS have been identified as an event upstream of ER stress able to lead to protein misfolding in the ER and ER stress-induced apoptosis ([@B53]; [@B62]). Additionally, it has been found that CS is able to cause expression of CHOP, the induction of which has been demonstrated to be ROS-dependent. However, the antioxidants MnTM-2-PyP and NAC are able to inhibit the pro-apoptotic effect of CS in human bronchial epithelial cells ([@B53]). In our previous work, JPYF II was shown to increase catalase (CAT) and glutathione peroxidase (GSH-Px) activity and reduce malondialdehyde (MDA) production in the lung tissues of a mouse model of LPS and CS-induced COPD, establishing the antioxidative properties of JPYF II ([@B12]). In this study, both JPYF II and the ROS inhibitor NAC diminished ROS levels and the expression of ER stress-related proteins, in addition to improving cell viability in bronchial epithelial cells exposed to CSE, indicating that JPYF II may suppress apoptosis induced by CSE in bronchial epithelial cells *via* the ROS-ER stress signaling pathway.

As is well known, ER is a major intracellular store of Ca^2+^in non-excitable cells ([@B3]; [@B47]). Interestingly, in addition to increasing the levels of ROS, leading to ER stress, CSE also increased intracellular Ca^2+^ concentration, indicating that intracellular Ca^2+^ homeostasis was disrupted by CSE-induced ER stress. A change in Ca^2+^ distribution or the loss of Ca^2+^ homeostasis can result in cell death ([@B64]). However, both JPYF II and the ER stress inhibitor TUDCA inhibited Ca^2+^ outflow from the ER and cell death. ER stress is accompanied by disruption of Ca^2+^ homeostasis. In addition, a decrease in ER Ca^2+^ concentration can trigger the accumulation of misfolded proteins resulting in ER stress ([@B39]; [@B4]). In the present study, JPYF II, the Ca^2+^ scavenger BAPTA-AM and the specific IP~3~R inhibitor 2-APB all inhibited CSE-induced ER stress and cell death. These results indicate that JPYF II may suppress bronchial epithelial cell apoptosis induced by CSE *via* the ER stress-Ca^2+^ pathway, while IP~3~R mediates Ca^2+^ release from the ER.

In summary, *in vitro* and *in vivo* experiments in the present study demonstrate that JPYF II can provide a protective effect against bronchial epithelial cell apoptosis in CS-induced COPD in mice and the apoptosis of CSE-stimulated BEAS-2B and 16-HBE cells. The anti-apoptotic effect might be related to interruption of the ROS-ER stress-Ca^2+^ signaling pathway. Hence, our findings provide a theoretical basis for further study and the treatment of COPD using JPYF II.

Data Availability Statement {#s5}
===========================

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

Ethics Statement {#s6}
================

The animal study was reviewed and approved by The Institutional Animal Care and Use Committee of Guangdong Provincial Academy of Chinese Medical Sciences.

Author Contributions {#s7}
====================

LF and LengL performed the experiments and wrote the draft of the manuscript. XY, ZL, TC, and YC helped with the animal study and sample preparation. YX and TH revised the manuscript. LW and LinL conceived and designed the experiments.

Funding {#s8}
=======

This study was financially supported by the National Natural Science Foundation of China (grant numbers 81573895, 81673897 and 81603554).

Conflict of Interest {#s9}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material {#s10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2020.00581/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Ismail Laher, University of British Columbia, Canada

[^2]: Reviewed by: Aljawharah Alqathama, Umm al-Qura University, Saudi Arabia; Cinzia Antognelli, University of Perugia, Italy

[^3]: This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

[^4]: †These authors have contributed equally to this work and share first authorship
